FDA Brief

Warning letters Drugs

FDA warning letter to

AACE Pharmaceuticals, Inc.

High riskIssued May 13, 2025Posted May 27, 2025Center for Drug Evaluation and Research (CDER)

AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.

What happened

FDA inspected AACE's Fairfield, NJ facility from Nov 12 to 22, 2024, after finding CGMP violations at Brassica, its CMO for ophthalmic drugs. The Brassica inspection (Jan 15-19, 2024) found poor aseptic practices, fabricated microbiology records, and microbial contamination. AACE imported and distributed Lubricant PM Ointment from Brassica despite knowing 2020 deficiencies, and its quality unit failed to adequately qualify the CMO.

What FDA found

  1. Quality unit lacked adequate supplier qualification procedures to ensure CMO-made drugs were CGMP-compliant before distribution.

    21 CFR 211.22(a)
  2. Released Lubricant PM Ointment for distribution without adequate procedures to ensure quality attributes.

    21 CFR 211.22(a)
  3. Qualified Brassica as an approved CMO despite known CGMP deficiencies and requalified without evaluating corrective actions.

    21 CFR 211.22(a)
  4. Received adulterated drugs in interstate commerce and delivered or offered them for delivery.

    FD&C Act section 301(c), 21 U.S.C. 331(c)
  5. Introduced adulterated drugs into interstate commerce.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

Provide a detailed plan to ensure you do not receive or deliver adulterated drugs, including evaluating current CMOs, improving qualification procedures, and conducting periodic audits; clarify whether you intend to distribute ophthalmic or sterile drugs for the U.S. market. Respond in writing within 15 working days.

Who should pay attention

  • companies that distribute or private-label ophthalmic drugs made by contract manufacturers
  • drug manufacturers using CMOs for sterile products
  • quality teams responsible for supplier qualification and CMO oversight

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk